摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-[(Diethoxyphosphinyl)methyl]benzenepropanoic acid | 95272-47-2

中文名称
——
中文别名
——
英文名称
α-[(Diethoxyphosphinyl)methyl]benzenepropanoic acid
英文别名
benzyl 3-(diethoxyphosphoryl)-2(R,S)-propionic acid;2(R,S)-benzyl-3-diethoxyphosphorylpropionic acid;2-Benzyl-3-(diethoxyphosphinyl)propionic acid;2-benzyl-3-diethoxyphosphorylpropanoic acid
α-[(Diethoxyphosphinyl)methyl]benzenepropanoic acid化学式
CAS
95272-47-2
化学式
C14H21O5P
mdl
——
分子量
300.292
InChiKey
OPMNUPKKGGXJHG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    20
  • 可旋转键数:
    9
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2S,4S,5S)-5-[(S)-2-Amino-3-(1H-imidazol-4-yl)-propionylamino]-6-cyclohexyl-4-hydroxy-2-isopropyl-hexanoic acid butylamide 、 α-[(Diethoxyphosphinyl)methyl]benzenepropanoic acid1-羟基苯并三唑N,N'-二环己基碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 (2S,4S,5S)-5-[[(2S)-2-[(2-benzyl-3-diethoxyphosphorylpropanoyl)amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-N-butyl-6-cyclohexyl-4-hydroxy-2-propan-2-ylhexanamide
    参考文献:
    名称:
    Synthesis and biological activity of some transition-state inhibitors of human renin
    摘要:
    A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.
    DOI:
    10.1021/jm00117a027
  • 作为产物:
    描述:
    参考文献:
    名称:
    Synthesis and biological activity of some transition-state inhibitors of human renin
    摘要:
    A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.
    DOI:
    10.1021/jm00117a027
点击查看最新优质反应信息

文献信息

  • N-morpholino derivatives and their use as anti-hypertensive agents
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05055466A1
    公开(公告)日:1991-10-08
    Compounds of the formula ##STR1## are disclosed. These compounds are inhibitors of renin and therefore useful as cardiovascular agents.
    公开了式##STR1##的化合物。这些化合物是肾素抑制剂,因此可用作心血管药物。
  • Novel 5-amino-4-hydroxyvaleryl derivatives
    申请人:Ciba-Geigy Corporation
    公开号:US04727060A1
    公开(公告)日:1988-02-23
    Compounds of the formula ##STR1## in which R.sub.1 represents hydrogen or acyl, A represents an optionally N-alkylated .alpha.-amino acid residue which is bonded N-terminally to R.sub.1 and C-terminally to the group --NR.sub.2 --, R.sub.2 represents hydrogen or lower alkyl, R.sub.3 represents hydrogen, lower alkyl, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl-lower alkyl, tricycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R.sub.4 represents hydroxy or etherified or esterified hydroxy, R.sub.5 represents lower alkyl having 2 or more carbon atoms, optionally etherified or esterified hydroxy-lower alkyl, cycloalkyl, cycloalkyl-lower alkyl, bicycloalkyl, bicycloalkyl-lower alkyl, tricycloalkyl, tricycloalkyl-lower alkyl, aryl, aryl-lower alkyl, optionally substituted carbamoyl, optionally substituted amino, optionally substituted hydroxy or optionally substituted mercapto and R.sub.6 represents substituted amino, and salts of such compounds having salt-forming groups inhibit the blood pressure-increasing action of the enzyme renin and can be used as antihypertensives.
    式为##STR1##的化合物,其中R.sub.1代表氢或酰基,A代表一个可选的N-烷基化的α-氨基酸残基,其N-末端与R.sub.1和C-末端与--NR.sub.2--基团连接,R.sub.2代表氢或较低的烷基,R.sub.3代表氢、较低烷基、可选地醚化或酯化的羟基较低烷基、环烷基、环烷基较低烷基、双环烷基较低烷基、三环烷基较低烷基、芳基或芳基较低烷基,R.sub.4代表羟基或醚化或酯化的羟基,R.sub.5代表具有2个或更多碳原子的较低烷基、可选地醚化或酯化的羟基较低烷基、环烷基、环烷基较低烷基、双环烷基、双环烷基较低烷基、三环烷基、三环烷基较低烷基、芳基、芳基较低烷基、可选地取代的氨基甲酰基、可选地取代的氨基、可选地取代的羟基或可选地取代的巯基,R.sub.6代表取代的氨基,以及具有形成盐的基团的这类化合物的盐,抑制肾素酶增加血压的作用,可用作降压药。
  • Pharmaceutical amides, and preparation, formulations and use of thereof
    申请人:The Wellcome Foundation Ltd.
    公开号:US04423242A1
    公开(公告)日:1983-12-27
    Compounds of the general formula ##STR1## wherein Ph is a phenyl group which is optionally substituted by one or more substituents selected from halo (i.e. fluoro, chloro, bromo or iodo), C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, nitro, sulphonyl, aminosulphonyl, trihalomethyl, carboxy, C.sub.1-4 alkoxycarbonyl, amido, C.sub.1-4 alkylamido C.sub.1-4 alkoxy, C.sub.2-4 alkenyl, cyano, aminomethyl or methylsulphonyl; R.sup.a and R.sup.b, which may be the same or different, each represents a hydrogen or alkali metal (e.g. sodium or lithium) atom or a C.sub.1-4 (e.g. ethyl) group; m is 0 or 1; Y is a group of formula: --NH--CH.sub.2 --CO-- or a group of formula: ##STR2## where R.sup.1 is hydrogen or methyl; R.sup.2 is alkyl of 1 to 3 carbon atoms or is methylthiomethyl; and Z is --OR.sup.3 or --NR.sup.4 R.sup.5 where R.sup.3, R.sup.4 and R.sup.5 are each hydrogen or alkyl of 1 to 4 carbon atoms (i.e. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl) and R.sup.3 can further be phenylalkyl having 1 to 3 carbon atoms in the alkylene moiety thereof, or phenyl; and basic salts thereof. These compounds have an advantageous enkephalinase inhibitory activity which renders the compounds useful in medical therapy, e.g. to prolong and/or potentiate in a mammal, the effects of endogenous or exogenous enkephalins. The latter includes synthetic enkepalin analogues.
    一般式为##STR1##的化合物,其中Ph是苯基,可选地取代为一个或多个取代基,所选取代基包括卤素(即氟、氯、溴或碘)、C.sub.1-4烷基、氨基、C.sub.1-4烷基氨基、二-C.sub.1-4烷基氨基、硝基、磺酰基、氨基磺酰基、三卤甲基、羧基、C.sub.1-4烷氧基羰基、酰胺基、C.sub.1-4烷基酰胺基、C.sub.1-4烷氧基、C.sub.2-4烯基、氰基、氨甲基或甲磺酰基;R.sup.a和R.sup.b,可以相同也可以不同,分别代表氢或碱金属(例如钠或锂)原子或C.sub.1-4(例如乙基)基团;m为0或1;Y是公式:--NH--CH.sub.2 --CO--或公式:##STR2##的基团,其中R.sup.1是氢或甲基;R.sup.2是1至3个碳原子的烷基或甲基硫代甲基;Z是--OR.sup.3或--NR.sup.4 R.sup.5,其中R.sup.3、R.sup.4和R.sup.5分别是氢或1至4个碳原子的烷基(即甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基),并且R.sup.3还可以是具有1至3个碳原子的烷基链的苯基烷基,或苯基;以及它们的盐。这些化合物具有有利的脑啡肽酶抑制活性,使得这些化合物在医疗治疗中有用,例如在哺乳动物中延长和/或增强内源性或外源性脑啡肽的效果,后者包括合成的脑啡肽类似物。
  • Pharmaceutical compounds, and preparation, formulations and use thereof
    申请人:THE WELLCOME FOUNDATION LIMITED
    公开号:EP0075334A2
    公开(公告)日:1983-03-30
    Compounds of the general formula wheren Ph is a phenyl group which is optionally substituted by one or more substituents selected from halo (i.e. fluoro, chloro, bromo or iodo), C1-4alkyl, amino, C1-4alkylamino, di-C1-4alkylamino, nitro, sulphonyl, aminosulphonyl, trihalomethyl, carboxy, C1-4alkoxycarbonyl, amido, C1-4alky(amido C1-4alkoxy, C2-4alkenyl, cyano, aminomethyl or methylsulphonyl; R' und Rb, which may be the same or different, each represents a hydrogen or alkali metal (eg. sodium or lithium) atom or a C1-4 (eg. ethyl) group; m is 0 or 1; Y is a group of formula: or a group of formula: where R' is hydrogen or methyl; R2 is alkyl of 1 to 3 carbon atoms or is methylthiomethyl; and Z is -OR3 or -NR4Rs where R3, R4 and R5 are each hydrogen or alkyl of 1 to 4 carbon atoms (ie. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or t-butyl) and R3 can further be phenylalkyl having 1 to 3 carbon atoms in the alkylene moiety thereof, or phenyl; and basic salts thereof. These compounds have an advantageous enkephalinase inhibitor activity which renders the compounds useful in medical therapy, eg. to prolong and/or potentiate in a mammal, the effects of endogenous or exogenous enkephalins. The latter includes synthetic enkephalin analogues.
    通式如下的化合物 其中 Ph 是苯基,可任选被一个或多个取代基取代,这些取代基选自卤代(即C1-4烷基、氨基、C1-4烷基氨基、二-C1-4烷基氨基、硝基、磺酰基、氨磺酰基、三卤甲基、羧基、C1-4烷氧基羰基、氨基、C1-4烷氧基、C2-4烯基、氰基、氨甲基或甲基磺酰基;R'和 Rb 可以相同或不同,各自代表氢原子或碱金属(如钠或锂)原子或 C1-4(如乙烯基)原子。m为 0 或 1; Y 是式中的基团 或式 其中 R' 是氢或甲基; R2 是 1 至 3 个碳原子的烷基或甲硫基;以及 Z是-OR3或-NR4Rs,其中R3、R4和R5各自是氢或1至4个碳原子的烷基(即甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基),R3还可以是在其亚烷基中具有1至3个碳原子的苯基烷基或苯基;以及它们的碱式盐。这些化合物具有良好的脑啡肽酶抑制剂活性,可用于医学治疗,例如延长和/或增强哺乳动物体内的内源性或外源性脑啡肽的作用。后者包括合成的脑啡肽类似物。
  • Phosphorous containing compounds as inhibitors of enkephalinases
    申请人:SCHERING CORPORATION
    公开号:EP0117429A1
    公开(公告)日:1984-09-05
    Compounds having the general formula in which W is R' or OR', R' being hydrogen, alkyl, phenyl or benzyl Xis-(CH2)P-CHR3 or CHR3-(CH2)p- R33 is chosen from various substituents, or Z is chosen from various of organic groups, and R2 forms, with the carbonyl group to which it is attached, carboxy or various esterified carboxy groups or is the group -NR8R9. The compounds inhibit the activity of enkephalinases. Intermediates of formula are disclosed in which Wa is alkoxy, phenoxy or benzyloxy Xa is CH2CH-, and Ya is -NH2 or -NCO.
    具有通式的化合物,其中 W 是 R'或 OR',R'是氢、烷基、苯基或苄基,Xis-(CH2)P-CHR3 或 CHR3-(CH2)p- R33 可从各种取代基中选择,或 Z 可从各种有机基团中选择,R2 与所连接的羰基形成羧基或各种酯化羧基,或为基团 -NR8R9。 这些化合物可抑制脑啡肽酶的活性。 公开了式中的中间体,其中 Wa 是烷氧基、苯氧基或苄氧基,Xa 是 CH2CH-,Ya 是 -NH2 或 -NCO。
查看更多